Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

MLA

Fox, Edward, et al. “Outcomes of Switching Directly to Oral Fingolimod from Injectable Therapies: Results of the Randomized, Open-Label, Multicenter, Evaluate Patient OutComes (EPOC) Study in Relapsing Multiple Sclerosis.” Multiple Sclerosis and Related Disorders, vol. 3, no. 5, Sept. 2014, pp. 607–19. EBSCOhost, https://doi.org/10.1016/j.msard.2014.06.005.

APA

Fox, E., Edwards, K., Burch, G., Wynn, D. R., LaGanke, C., Crayton, H., Hunter, S. F., Huffman, C., Kim, E., Pestreich, L., McCague, K., & Barbato, L. (2014). Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 3(5), 607–619. https://doi.org/10.1016/j.msard.2014.06.005

Chicago

Fox, Edward, Keith Edwards, Gordon Burch, Daniel R Wynn, Chris LaGanke, Heidi Crayton, Samuel F Hunter, et al. 2014. “Outcomes of Switching Directly to Oral Fingolimod from Injectable Therapies: Results of the Randomized, Open-Label, Multicenter, Evaluate Patient OutComes (EPOC) Study in Relapsing Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 3 (5): 607–19. doi:10.1016/j.msard.2014.06.005.